Nonspecific non-toxic or slightly toxic antitumor immunomodulators, necessary to increase the antitumor resistance of the body, are increasingly used in complex treatment and for the prevention of malignant neoplasms, which is justified, firstly, by the fact that the progression of a tumor disease is usually accompanied by the development of an immunodeficiency state and, in secondly, by the fact that the presence of specific tumor-associated antigens of various genesis was found on the surface of cancer cells, which, however, do not always cause a tense immune response.

AstroMelanin successfully passed the mandatory primary screening (selection) of compounds for immunomodulating activity in in vitro experiments, showed a pronounced immunomodulating effect in model reactions of cellular immunity (for the formation of T-lymphocytes). Since it is known that among the variety of cells involved in immunological surveillance, T-lymphocytes, which play a significant role in antitumor immunity, are especially important, the identification of a new drug that affects the formation of T-lymphocytes is especially important for these purposes and for the final conclusion on the appropriateness of use.

In the treatment of AstroMelanin orally at 10 mg 3 times a day in an aqueous solution (total 1 g of the substance) of two volunteer patients with breast adenocarcinoma and squamous cell carcinoma of the cervix, a shift of all immunoparameters towards the norm or entry into the norm was found.